ClinicalTrials.gg

Program

selcodebart

Its studies are mostly in Primary Myelofibrosis · Inflammatory Bowel Diseases · Renal Insufficiency, Chronic, led by Disc Medicine.

Furthest: phase 2, since Mar 15, 20224 company-led studies, 2 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Disc Medicine42 open or runningphase 2since Mar 15, 2022Jul 20, 2021May 2027phase 2 · NCT05320198

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 20, 2021First study: phase 1 study in Healthy VolunteerFirst studyNCT04999527 · 42 enrolled · United States
  2. Mar 15, 2022Phase 2 study in Primary MyelofibrosisNCT05320198 · 150 planned · United States, Australia
  3. Feb 16, 2023Phase 1 study in Renal Insufficiency, ChronicNCT05745883 · 55 enrolled · United States
  4. Jan 22, 2026Phase 2 study in Inflammatory Bowel DiseasesNCT07368972 · 21 planned · United States

Ahead

  1. May 2027Primary completion: phase 2 study in Primary MyelofibrosisNCT05320198

TargetBeta

HJV →read by rule
“A humanized monoclonal antibody directed against the bone morphogenetic proteins (BMPs) co-receptor hemojuvelin (HJV), ”NCIt, by rule

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07368972Inflammatory Bowel Diseases · United States2RecruitingOct 202621
NCT05745883Renal Insufficiency, Chronic · United States1CompletedOct 9, 202555
NCT05320198Primary Myelofibrosis · United States, Australia2RecruitingMay 2027150
NCT04999527Healthy Volunteer · United States1CompletedJun 30, 202242

How it is read

Names in the registry

  • “DISC-0974”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.